Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free Clinics - 1

This study has been completed.
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00033007
First received: April 5, 2002
Last updated: April 13, 2010
Last verified: April 2010
  Purpose

The purpose of this study is to test the utilization of incentive values (considerably lower than those typically used in research clinics) to motivate clients to attend treatment and initiate and sustain abstinence.


Condition Intervention Phase
Substance-Related Disorders
Behavioral: Behavior Therapy
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free Clinics

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • ASI
  • Cocaine use
  • AIDS risk behavior

Estimated Enrollment: 440
Study Start Date: April 2001
Study Completion Date: February 2003
Primary Completion Date: February 2003 (Final data collection date for primary outcome measure)
Detailed Description:

The purpose of the proposed research is to implement and systematically evaluate, in community treatment settings, motivational incentive procedures that have been well researched and have proven efficacious in a variety of treatment research clinics.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criterea:

  • New intake to a drug-free CTP
  • Evidence of cocaine or methamphetamine use, any reported use in past 2 weeks or positive urine screen at study intake. For those exiting a controlled environment, any stimulant use within two weeks of entering the controlled environment

Exclusion Criteria:

  • Unable to give informed consent (fails simple consent quiz)
  • Answers yes to question: Are you in recovery from gambling? That is, have you stopped gambling because of previous problems with gambling?
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00033007

Locations
United States, California
MATRIX/LA Addictions Research
Los Angeles, California, United States, 90025
United States, Colorado
Crossroads Managed Care Systems - Alamosa
Alamosa, Colorado, United States, 81101
Arapahoe/Douglas Mental Health Network
Littleton, Colorado, United States, 80120
Crossroads Managed Care Systems - Pueblo
Pueblo, Colorado, United States, 81001
Crossroads Managed Care Systems - Trinidad
Trinidad, Colorado, United States, 81082
United States, Connecticut
LMG Programs, Inc.
Stamford, Connecticut, United States, 06901
United States, Maryland
Harbel Prevention and Recovery Center
Baltimore, Maryland, United States, 21214
United States, Pennsylvania
Thomas Jefferson Intensive Sub. Abuse TP
Philadelphia, Pennsylvania, United States, 19107
United States, South Carolina
Charleston Center
Charleston, South Carolina, United States, 29403
Circle Park Behavioral Health Services - Florence
Florence, South Carolina, United States, 29502
Circle Park Behavioral Health Services - Lake City
Florence, South Carolina, United States, 29502
Sponsors and Collaborators
Johns Hopkins University
Investigators
Principal Investigator: Maxine Stitzer, Ph.D. Johns Hopkins University
  More Information

No publications provided

Responsible Party: Maxine Stitzer, Ph.D., Johns Hopkins Bayview Medical Center
ClinicalTrials.gov Identifier: NCT00033007     History of Changes
Obsolete Identifiers: NCT00015405
Other Study ID Numbers: NIDA-CTN-0006-1
Study First Received: April 5, 2002
Last Updated: April 13, 2010
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders

ClinicalTrials.gov processed this record on September 11, 2014